10. SUBSEQUENT EVENTS
|9 Months Ended|
Sep. 30, 2016
|Notes to Financial Statements|
|NOTE 10 - SUBSEQUENT EVENTS||
The Company has evaluated events and transactions that occurred from September 30, 2016 through the date of filing, for possible disclosure and recognition in the financial statements. See discussed below material subsequent events that impact its financial statements or disclosures.
On October 13, 2016, the Company issued a press release that announced that the Company along with its partner company, Advance Pharmaceutical Co., Ltd., which holds a license for the Company’s products in Asia, received a grant from the Research and Development Cash Rebate Program of up to $400,000 (USD) from the Hong Kong Innovation and Technology Commission (ITC), which will be used for a feasibility study of a novel way to safely and accurately self-screen and facilitate risk management associated with the onset of diabetes and other vascular disease-related states including stroke and cardiovascular disease.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
No definition available.